March 31, 2021
Achilles Therapeutics plc, a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, has announced the pricing of its initial public offering in the United States of 9,750,000 American Depositary Shares (ADSs) representing 9,750,000 ordinary shares at an initial public offering price of US$18 per ADS for total gross proceeds of US$175.5 million. All ADSs sold in the offering are being offered by Achilles. The ADSs are expected to begin trading on The Nasdaq Global Select Market on March 31, 2021 under the ticker symbol “ACHL.” In addition, Achilles has granted the underwriters a 30-day option to purchase up to an additional 1,462,500 ADSs at the initial public offering price, less underwriting discounts and commissions. The offering is expected to close on April 6, 2021, subject to customary closing conditions.
Latham & Watkins LLP represented the underwriters in the offering with a capital markets team led by New York partner Nathan Ajiashvili, with New York associates Salvatore Vanchieri and Angel Marcial, and London associate Laura Harper.